Incidental reduction in the size of liver hemangioma following use of VEGF inhibitor bevacizumab

Dipti Mahajan, Charles Miller, Kenzo Hirose, Arthur McCullough, Lisa Yerian

Research output: Contribution to journalArticle

Abstract

Background/Aims: Hepatic cavernous hemangioma is the second most common liver tumor after metastases. Vascular endothelial growth factor (VEGF) is recognized as an essential regulator of blood vessel growth. High VEGF expression leads to increased angiogenic activity in cavernous hemangioma endothelial cells. The use of specific antibodies directed against VEGF abolishes this vascular endothelial growth-promoting activity in vitro. Bevacizumab is a recombinant humanized monoclonal antibody directed against VEGF which is used for the treatment of metastatic colorectal cancer in combination with 5-fluorouracil-based regimens. Methods: We report a patient with invasive colorectal adenocarcinoma and suspected liver metastasis on radiological examination, who showed a significant decrease in the size of his liver lesions after bevacizumab treatment. Histology of the liver lesions revealed hemangioma with a strong staining for VEGF and anti-VEGFr2 antibody in the hemangioma endothelial cells. To date, surgical resection provides the only consistently effective method for treatment of hepatic hemangioma. Conclusions: This is the first documented case of hepatic hemangioma responsive to antiangiogenic therapy, suggesting a possible use for these agents in treating symptomatic patients without surgery. VEGF-signaling blockade including bevacizumab use poses a potential new treatment modality for vascular neoplasms in the liver and other sites.

Original languageEnglish (US)
Pages (from-to)867-870
Number of pages4
JournalJournal of Hepatology
Volume49
Issue number5
DOIs
StatePublished - Nov 2008
Externally publishedYes

Fingerprint

Hemangioma
Vascular Endothelial Growth Factor A
Liver
Cavernous Hemangioma
Blood Vessels
Endothelial Cells
Vascular Neoplasms
Neoplasm Metastasis
Therapeutics
Antibodies, Monoclonal, Humanized
Bevacizumab
Fluorouracil
Anti-Idiotypic Antibodies
Colorectal Neoplasms
Histology
Adenocarcinoma
Staining and Labeling
Antibodies
Growth

Keywords

  • Angiogenesis
  • Bevacizumab
  • Hemangioma
  • Vascular endothelial growth factor (VEGF)

ASJC Scopus subject areas

  • Hepatology

Cite this

Incidental reduction in the size of liver hemangioma following use of VEGF inhibitor bevacizumab. / Mahajan, Dipti; Miller, Charles; Hirose, Kenzo; McCullough, Arthur; Yerian, Lisa.

In: Journal of Hepatology, Vol. 49, No. 5, 11.2008, p. 867-870.

Research output: Contribution to journalArticle

Mahajan, Dipti ; Miller, Charles ; Hirose, Kenzo ; McCullough, Arthur ; Yerian, Lisa. / Incidental reduction in the size of liver hemangioma following use of VEGF inhibitor bevacizumab. In: Journal of Hepatology. 2008 ; Vol. 49, No. 5. pp. 867-870.
@article{94d7427e60e2463081166a53c25b5102,
title = "Incidental reduction in the size of liver hemangioma following use of VEGF inhibitor bevacizumab",
abstract = "Background/Aims: Hepatic cavernous hemangioma is the second most common liver tumor after metastases. Vascular endothelial growth factor (VEGF) is recognized as an essential regulator of blood vessel growth. High VEGF expression leads to increased angiogenic activity in cavernous hemangioma endothelial cells. The use of specific antibodies directed against VEGF abolishes this vascular endothelial growth-promoting activity in vitro. Bevacizumab is a recombinant humanized monoclonal antibody directed against VEGF which is used for the treatment of metastatic colorectal cancer in combination with 5-fluorouracil-based regimens. Methods: We report a patient with invasive colorectal adenocarcinoma and suspected liver metastasis on radiological examination, who showed a significant decrease in the size of his liver lesions after bevacizumab treatment. Histology of the liver lesions revealed hemangioma with a strong staining for VEGF and anti-VEGFr2 antibody in the hemangioma endothelial cells. To date, surgical resection provides the only consistently effective method for treatment of hepatic hemangioma. Conclusions: This is the first documented case of hepatic hemangioma responsive to antiangiogenic therapy, suggesting a possible use for these agents in treating symptomatic patients without surgery. VEGF-signaling blockade including bevacizumab use poses a potential new treatment modality for vascular neoplasms in the liver and other sites.",
keywords = "Angiogenesis, Bevacizumab, Hemangioma, Vascular endothelial growth factor (VEGF)",
author = "Dipti Mahajan and Charles Miller and Kenzo Hirose and Arthur McCullough and Lisa Yerian",
year = "2008",
month = "11",
doi = "10.1016/j.jhep.2008.06.028",
language = "English (US)",
volume = "49",
pages = "867--870",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Incidental reduction in the size of liver hemangioma following use of VEGF inhibitor bevacizumab

AU - Mahajan, Dipti

AU - Miller, Charles

AU - Hirose, Kenzo

AU - McCullough, Arthur

AU - Yerian, Lisa

PY - 2008/11

Y1 - 2008/11

N2 - Background/Aims: Hepatic cavernous hemangioma is the second most common liver tumor after metastases. Vascular endothelial growth factor (VEGF) is recognized as an essential regulator of blood vessel growth. High VEGF expression leads to increased angiogenic activity in cavernous hemangioma endothelial cells. The use of specific antibodies directed against VEGF abolishes this vascular endothelial growth-promoting activity in vitro. Bevacizumab is a recombinant humanized monoclonal antibody directed against VEGF which is used for the treatment of metastatic colorectal cancer in combination with 5-fluorouracil-based regimens. Methods: We report a patient with invasive colorectal adenocarcinoma and suspected liver metastasis on radiological examination, who showed a significant decrease in the size of his liver lesions after bevacizumab treatment. Histology of the liver lesions revealed hemangioma with a strong staining for VEGF and anti-VEGFr2 antibody in the hemangioma endothelial cells. To date, surgical resection provides the only consistently effective method for treatment of hepatic hemangioma. Conclusions: This is the first documented case of hepatic hemangioma responsive to antiangiogenic therapy, suggesting a possible use for these agents in treating symptomatic patients without surgery. VEGF-signaling blockade including bevacizumab use poses a potential new treatment modality for vascular neoplasms in the liver and other sites.

AB - Background/Aims: Hepatic cavernous hemangioma is the second most common liver tumor after metastases. Vascular endothelial growth factor (VEGF) is recognized as an essential regulator of blood vessel growth. High VEGF expression leads to increased angiogenic activity in cavernous hemangioma endothelial cells. The use of specific antibodies directed against VEGF abolishes this vascular endothelial growth-promoting activity in vitro. Bevacizumab is a recombinant humanized monoclonal antibody directed against VEGF which is used for the treatment of metastatic colorectal cancer in combination with 5-fluorouracil-based regimens. Methods: We report a patient with invasive colorectal adenocarcinoma and suspected liver metastasis on radiological examination, who showed a significant decrease in the size of his liver lesions after bevacizumab treatment. Histology of the liver lesions revealed hemangioma with a strong staining for VEGF and anti-VEGFr2 antibody in the hemangioma endothelial cells. To date, surgical resection provides the only consistently effective method for treatment of hepatic hemangioma. Conclusions: This is the first documented case of hepatic hemangioma responsive to antiangiogenic therapy, suggesting a possible use for these agents in treating symptomatic patients without surgery. VEGF-signaling blockade including bevacizumab use poses a potential new treatment modality for vascular neoplasms in the liver and other sites.

KW - Angiogenesis

KW - Bevacizumab

KW - Hemangioma

KW - Vascular endothelial growth factor (VEGF)

UR - http://www.scopus.com/inward/record.url?scp=53449093725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53449093725&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2008.06.028

DO - 10.1016/j.jhep.2008.06.028

M3 - Article

C2 - 18814928

AN - SCOPUS:53449093725

VL - 49

SP - 867

EP - 870

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 5

ER -